Browse the evidence

SIRT1 negatively regulates mTOR signaling through interaction with the TSC1/2 complex, and its activation by resveratrol reduces mTOR activity in a SIRT1-dependent manner.

This research identifies a specific biological pathway where SIRT1 (often activated by caloric restriction or compounds like resveratrol) inhibits mTOR, a key driver of cell growth and aging. While this is a mechanistic study in cells and mice, it suggests that strategies promoting SIRT1 activity may help regulate mTOR signaling, potentially offering benefits for age-related health.

Activation of mesolimbic GLP-1 receptors (specifically in the ventral tegmental area and nucleus accumbens) by the GLP-1 analog Exendin-4 directly reduces the rewarding value and motivation for palatable food without inducing malaise.

This research indicates that GLP-1 based therapies (like Exendin-4) may work by changing how your brain values food, specifically by reducing the 'reward' or 'craving' for palatable foods, rather than just making you feel physically full or sick. This happens by acting on specific reward centers in the brain (VTA and NAc). For someone managing weight, this suggests that the effectiveness of GLP-1 medications might be partly due to reducing the psychological drive to eat high-reward foods, independent of nausea.

Neuronal GLP1 receptors (GLP1R) are necessary for the anorectic (appetite-suppressing) and weight-loss effects of the long-acting GLP1 agonist liraglutide, but are not required for its glucose-lowering effects.

For patients using GLP-1 agonists like liraglutide for weight loss, understanding that the drug works by acting on the brain is key. The weight loss is driven by central nervous system receptors, not just peripheral gut signals. This explains why the medication reduces appetite centrally. However, the blood sugar benefits occur through different pathways, likely directly on the pancreas, meaning glucose control can be achieved even if the appetite-suppressing effects are blunted.

The E3 ubiquitin ligase MAFbx (Atrogin-1) directly binds to MyoD via a conserved LXXLL motif interaction, leading to MyoD ubiquitination and proteasomal degradation, which suppresses myogenic differentiation.

This research identifies MAFbx as a key enzyme that degrades MyoD, a master regulator of muscle growth. High levels of MAFbx, often seen during muscle atrophy (caused by fasting, aging, or disuse), lead to the loss of MyoD and inhibit muscle formation. Preserving muscle mass may involve mechanisms that regulate or inhibit MAFbx activity.

High dietary calcium intake increases thermogenesis and uncoupling protein-2 (UCP-2) expression, contributing to energy expenditure and weight loss independent of caloric restriction.

This mechanism is more relevant to understanding the biological basis of calcium's effect rather than a direct actionable step for humans, as the temperature increase is modest and observed in animal models.

Fetal exposure to severe famine increases the risk of hyperglycemia in adulthood, with the risk significantly exacerbated by an affluent or Western dietary pattern and higher economic status in later life.

If you were in utero during a major food shortage, your body may be biologically primed to store energy efficiently. In a modern environment with abundant food, this can lead to high blood sugar. To mitigate this, prioritize a diet lower in refined sugars and processed fats (avoiding the 'Western' pattern) and maintain a healthy weight, as these factors significantly reduce the elevated risk associated with your early life exposure.

Gut microbiota composition influences energy homeostasis and obesity development through mechanisms involving short-chain fatty acids (SCFAs), bile acid metabolism, and systemic inflammation.

If you are considering probiotics for weight management, look for specific strains like Lactobacillus casei Shirota, L. gasseri, L. rhamnosus, or L. plantarum, as well as Bifidobacterium infantis, longum, and breve. However, do not expect all probiotics to work, as some strains have shown no effect or even increased weight gain in studies.

Long-term severe calorie restriction (1-6 years) does not reduce serum IGF-1 or IGF-1:IGFBP-3 ratio in healthy humans, unlike the reduction observed in rodents.

If you are practicing long-term calorie restriction for health or longevity, do not expect your IGF-1 levels to drop significantly, even if you lose weight. This differs from what is seen in mice. Your body maintains IGF-1 levels despite the energy deficit, provided you are not malnourished.

Intensive glycaemic control in type 2 diabetes does not reduce all-cause or cardiovascular mortality compared to conventional control, but significantly increases the risk of severe hypoglycaemia.

For Type 2 Diabetes, aggressively lowering blood sugar to very low targets (like <6.0%) does not extend life and significantly increases the risk of severe hypoglycaemia. Standard guidelines (HbA1c <7.0%) are generally safer and equally effective for mortality prevention compared to intensive targets.

Pharmacological blockade of central melanocortin receptors (CNS-Mcr) directly promotes lipid uptake, triglyceride synthesis, and fat accumulation in white adipose tissue (WAT) independent of food intake.

If you have genetic or hormonal factors that impair your brain's ability to signal fat storage (like MC4R mutations), your body may store fat more aggressively even if you eat the same amount as others. This isn't a failure of willpower; it's a biological signal. Understanding this can help shift focus from just 'eating less' to addressing underlying metabolic health and hormonal balance.

Activation of central melanocortin receptors increases sympathetic nerve activity to white adipose tissue, leading to lipid mobilization and reduced fat storage.

Your brain uses your nervous system to tell your fat cells whether to store or burn fat. Activating certain brain receptors can signal your body to release stored fat, independent of how much you eat.

Obesity induces a pro-inflammatory state in adipose tissue characterized by elevated secretion of cytokines (TNF-α, IL-6, IL-8) and PAI-1, which contributes to insulin resistance and cardiovascular risk.

Your body fat is not just dead weight; it actively releases hormones and inflammatory signals that can make you resistant to insulin and increase heart disease risk. Losing weight, particularly visceral fat, can reverse this inflammatory state and improve metabolic health.

Metabolic syndrome, particularly through its components of obesity and insulin resistance, increases the risk of hepatocellular carcinoma (HCC) and worsens clinical outcomes, primarily mediated by the progression of nonalcoholic fatty liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) and cirrhosis.

If you have metabolic syndrome (obesity, high blood pressure, high blood sugar, or high triglycerides), your risk of liver cancer is significantly higher, even if you don't have hepatitis. This risk is driven by the progression of fatty liver to inflammation (NASH) and cirrhosis. Managing weight and insulin sensitivity is critical to reducing this risk.

Aging is associated with hyperactivation of the HPA axis, characterized by higher 24-hour mean cortisol levels and a shorter quiescent period.

Be aware that cortisol levels naturally rise with age. This may contribute to age-related metabolic changes. Prioritizing sleep quality and managing stress may help mitigate this natural increase.

Genetic deletion of Acetyl-CoA Carboxylase 2 (ACC2) protects against obesity and type 2 diabetes induced by high-fat/high-carbohydrate diets by increasing fatty acid oxidation and preventing intracellular lipid accumulation.

This research suggests that the inability to oxidize fatty acids efficiently (due to high malonyl-CoA levels from ACC2 activity) is a key driver of diet-induced obesity and insulin resistance. While this specific genetic modification is not a human intervention, it highlights that strategies enhancing fatty acid oxidation or reducing malonyl-CoA levels could be therapeutic targets for preventing obesity and type 2 diabetes in individuals consuming high-fat/high-carbohydrate diets.

In middle-aged women, short sleep duration is not significantly associated with incident diabetes; instead, long sleep duration (≥9 hours) shows a non-significant trend toward increased risk.

For middle-aged women, the link between short sleep and diabetes is not as clear-cut as it is for men. This study suggests that long sleep (≥9 hours) might be a marker for underlying health issues or risk, rather than short sleep being the primary driver. Women should focus on healthy sleep duration (7-8 hours) and consult a doctor if they consistently need very long sleep, as it may indicate other metabolic or health concerns.

Obesity causes supersaturated cholesterol bile primarily through excessive hepatic cholesterol secretion, not by a deficiency in bile acids or phospholipids.

If you are obese, your liver is likely secreting excess cholesterol into your bile, making you prone to gallstones. This is a metabolic consequence of obesity itself, not just what you eat. While weight loss reduces this risk, the underlying tendency is driven by the excess body fat altering liver secretion rates.

Dapagliflozin monotherapy reduces hepatocyte injury biomarkers and FGF21 levels, suggesting a disease-modifying effect on NAFLD/NASH, but this effect is negated when combined with OM-3CA.

Dapagliflozin alone (10 mg daily) significantly reduces markers of liver cell injury (such as AST, ALT, and GGT) and FGF21 in patients with Type 2 Diabetes and NAFLD, suggesting it may modify the disease. However, adding OM-3CA (4 g daily) negates this specific benefit on injury biomarkers, even though the combination is superior for reducing total liver fat.

Melatonin acts as a mitochondria-targeted antioxidant by accumulating in high concentrations within mitochondria via oligopeptide transporters (PEPT1/2), where it directly scavenges reactive oxygen species (ROS) and stimulates antioxidant enzymes (SOD, GPx) to mitigate oxidative stress and age-related decline.

Melatonin is not just a sleep hormone; it is a potent antioxidant that concentrates inside your cells' energy producers (mitochondria). This positioning allows it to neutralize damaging free radicals more effectively than many other antioxidants, potentially slowing age-related cellular decline. While the paper focuses on mechanisms, this suggests that maintaining healthy melatonin rhythms or supplementation could support long-term cellular health.

Higher body mass index (BMI) and waist circumference (WC) are significantly associated with altered DNA methylation levels at specific genomic loci (including CPT1A, ABCG1, and HIF3A) in leukocytes, and these epigenetic signatures replicate across different ethnicities and tissue types, suggesting a biological link between adiposity and gene regulation.

This research confirms that carrying excess weight leaves a measurable 'epigenetic signature' on your blood cells, involving genes related to metabolism and inflammation. While the effect size of any single gene is small, the cumulative pattern is robust and replicable. Crucially, because these marks are modifiable, maintaining a healthy weight or losing weight may help normalize these epigenetic patterns, potentially reducing long-term disease risk.

DNA methylation changes at loci such as CPT1A and ABCG1 are associated not just with current BMI, but with BMI change over time, suggesting these epigenetic markers may reflect dynamic metabolic history rather than just static adiposity.

Your body's epigenetic 'record' includes your history of weight gain or loss, not just your current size. This suggests that past weight fluctuations leave a lasting biological mark. While this doesn't change immediate dietary advice, it highlights the importance of sustainable weight management to avoid negative epigenetic impacts from yo-yo dieting or prolonged obesity.

The association between obesity and DNA methylation at loci like HIF3A is not universal across all populations; specifically, HIF3A methylation associated with BMI in African Americans and European adults did not replicate in White replication cohorts (FHS/GOLDN) in this study.

Not all genetic or epigenetic markers for obesity work the same way for everyone. The HIF3A marker, often cited in research, was not found to be associated with BMI in this study's White cohorts, highlighting the need for personalized medicine approaches rather than one-size-fits-all biomarkers.

Central nervous system regulation, particularly via the hypothalamus, is essential for homeostatic control of energy balance and glucose metabolism; defective brain-peripheral crosstalk contributes to obesity and type 2 diabetes.

Understanding that your brain plays a central role in regulating hunger, energy use, and blood sugar is key. If you struggle with obesity or diabetes, it may not just be about what you eat, but how your brain processes metabolic signals. Addressing central resistance (e.g., through lifestyle changes that improve brain insulin/leptin sensitivity) is as important as peripheral factors.

Leptin resistance in obesity involves impaired transport across the blood-brain barrier and defective hypothalamic signaling (e.g., STAT3, PI3K), leading to reduced satiety and energy expenditure.

In obesity, your body produces plenty of leptin, but your brain doesn't hear it. This 'leptin resistance' means you feel hungry and store fat more easily. Improving brain sensitivity to leptin (through weight loss, exercise, and sleep) is more effective than trying to add more leptin.